Actively Recruiting
Study of i3.1 Probiotic Treatment in Adults Aged 45 to 70 with MECFS, With or Without IBS
Led by Nova Southeastern University · Updated on 2025-03-04
100
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the use of the i3.1 probiotic in people aged 45 to 70 years who have Myalgic EncephalomyelitisChronic Fatigue Syndrome MECFS based on the Canadian Consensus Criteria. The study also includes participants who may have irritable bowel syndrome IBS diagnosed by Rome IV criteria. The trial aims to evaluate how well the probiotic reduces gastrointestinal inflammation and improves the gut and brain interface, as well as its effect on IBS severity. Participants will be randomly assigned to one of four groups those with MECFS with or without IBS, each receiving either the i3.1 probiotic Floradapt Intensive GI or a placebo. The probiotic or placebo is taken as one high-dose capsule daily for eight weeks. The study is double-blinded, meaning neither participants nor researchers know who receives the probiotic or placebo during treatment. Participants will be assessed at the start of the study, after eight weeks of treatment, and again at 12 weeks, four weeks after treatment ends. Researchers will monitor safety by recording any adverse events and measure blood biomarkers like C-reactive protein and pro-inflammatory cytokines. They will also evaluate symptom severity and IBS-related quality of life. Participants will complete online surveys and attend follow-up visits during the study period.
CONDITIONS
Brief Title
The Use of Directed Probiotics in ME/CFS: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Research Team
N
Nancy Klimas, MD
D
Devra Cohen, MPH
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here